���ϳԹ�

Figure 1. Production of CD13+ and CD15+ Myeloid Cells by the Expansion and Lineage-Specific Differentiation of Human BM-Derived Cells Cultured in StemSpan™ SFEM II Containing Myeloid Expansion Supplement

Flow cytometry dot plots for 14-day cultures of human BM-derived CD34+ cells in StemSpan™ SFEM II containing Myeloid Expansion Supplement showing expression of the HSPC marker CD34, and pan-hematopoietic marker CD45 (A) before and (B) after 14 days of culture, and expression of myeloid markers CD13 and CD15 (C) after 14 days of culture. The frequency of CD34+ cells declined from 83% before culture to ~1% after 14 days. In parallel, myeloid CD13+CD15+ cells gradually accumulated from <10% on day 0 to 46% by day 14. The frequency of CD14+ cells after culture was low (typically <10%, see Table 1).

Table 1. Production of Myeloid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ SFEM II Containing Myeloid Expansion Supplement

Number of total nucleated cells (TNCs) produced per input human CB-derived CD34+ cell from 14 different donors and percentage of cells positive for myeloid markers CD13, CD14 and CD15 produced after 14 days of culture in SFEM II containing Myeloid Expansion Supplement. Best expansion was obtained in SFEM II, but myeloid cell expansion may also be obtained in SFEM and ACF media.
*95% confidence limits (CL), the range within which 95% of the results will typically fall.